Changes in Registrant’s Certifying Accountant. On July 19, 2025, the audit committee of the Board of Directors of Greenwich LifeSciences, Inc. (the “Company”) approved the dismissal of RBSM LLP (“RBSM”) as the Company’s independent registered public accounting firm and approved the engagement of MaloneBailey LLP (“MaloneBailey”) as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ended December 31, 2025. Accordin…

by reference. The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securit…

Entry into a Material Definitive Agreement. On June 13, 2024, Greenwich LifeSciences, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with Snehal Patel, its Chief Executive Officer, pursuant to which the Company agreed to issue and sell to Mr. Patel, in a private placement, 174,825 shares (the “ Shares ”) of its common stock, par value $0.001 per share, at an offering price of $14.30 per share which was the Nasdaq Official Closing Price on June…

Changes in Registrant’s Certifying Accountant. On February 14, 2024, the audit committee of the Board of Directors of Greenwich LifeSciences, Inc. (the “Company”) approved the dismissal of MaloneBailey LLP (“Malone”) as the Company’s independent registered public accounting firm and approved the engagement of RBSM LLP (“RBSM”) as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ended December 31, 2023. Accordingl…

Entry into a Material Definitive Agreement. On July 12, 2022, Greenwich LifeSciences, Inc. (the “ Company ”) entered into an Open Market Sale Agreement (the “ Sale Agreement ”) with Jefferies LLC (“ Jefferies ”), as sales agent. Pursuant to the terms of the Sale Agreement, the Company may issue and sell from time to time shares of its common stock, par value $0.001 per share, through Jefferies, acting as its sales agent. Pursuant to the Company’s prospectus supplement filed on July 12, 2022,…

Entry into a Material Definitive Agreement. On December 17, 2020, Greenwich LifeSciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp., acting as the representative (the “Representative”) of the several underwriters (the “Underwriters”) named therein, with respect to an underwritten public offering (the “Offering”) of 660,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock…